Status:
COMPLETED
Post-coronavirus Disease-2019 Fatigue
Lead Sponsor:
Rabin Medical Center
Conditions:
Covid19
Post-COVID / Long-COVID
Eligibility:
All Genders
18+ years
Brief Summary
Background: COVID-19 is consistently spreading throughout the world, and the number of recovered patients is steadily increasing. Accordingly, a significant number of individuals will develop persisti...
Detailed Description
The evaluation of both cases and controls will include the following: * Physical examination: a comprehensive physical examination, including neurological assessment of motor function. * Blood tests:...
Eligibility Criteria
Inclusion
- • Adult individuals (age ≥18 years) recovered from COVID-19 (diagnosed using a polymerase chain reaction test from a nasopharyngeal sample), with or without lasting fatigue symptoms, which appeared following COVID-19, while at least two months have elapsed since COVID-19 diagnosis.
Exclusion
- Individuals hospitalized in intensive care unit and/or required mechanical ventilation during their acute illness.
- Individuals diagnosed with pulmonary veno-thromboembolism/pulmonary infarction, on current oxygen supplementation, with sleep apnea/hypopnea syndrome or with post-COVID-19 chest imaging suggesting pulmonary fibrosis.
- Individuals with heart failure, acute coronary syndrome or percutaneous cardiac intervention during the year prior to the diagnosis.
- Individuals who underwent surgical procedure under general anesthesia during the year prior to the diagnosis.
- Individuals with cerebrovascular disease and a history of cerebrovascular accident or transient ischemic attack.
- Individuals with paralysis of the lower limbs, amputees, bedridden, those assisted with walking aids or wheelchair.
- Individuals with myopathies or myositis, degenerative neurological or muscular diseases, and myasthenia gravis.
- Individuals with pre-COVID-19 diagnosis of chronic fatigue syndrome, fibromyalgia, major depressive disorder, obstructive sleep hypopnea/apnea syndrome, or sleep disturbance necessitating pharmacotherapy.
- Individuals with chronic illnesses (autoimmune diseases and malignancies) necessitating immunosuppression (including corticosteroid therapy) or immunomodulation (including anti-cancer agents).
- Individuals with thyroid dysfunction prior to their diagnosis with COVID-19: uncontrolled hypothyroidism or hyperthyroidism and those with imbalanced thyroid stimulating hormone (TSH) level.
- Pregnant women.
- Individuals with chronic use of opioids.
Key Trial Info
Start Date :
March 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 24 2021
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT04851561
Start Date
March 2 2021
End Date
August 24 2021
Last Update
October 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rabin Medical Center - Beilinson Hospital
Petah Tikva, Israel, 49100